Please login to the form below

Not currently logged in
Email:
Password:

People, June, 2010

Recent high-profile moves in the pharmaceutical and healthcare industries
Mover of the month is Steve Howson who has been appointed general manager of Ferring UK

Mover of the month

 
Steve Howson 

Steve Howson has been appointed general manager of Ferring UK, effective May 17. Steve will be responsible for the Ferring operations in the UK and Malta. He joins Ferring from his former position as chief operating officer of Medicsight, a medical imaging company specialising in the early detection of cancer. Over the last two years he has helped establish the commercial operation in target territories and contributed to laying the foundation for upcoming product launches.

Sarah Gipps has joined Lime Advertising from Adventis Health as account executive. David Williams also joins Lime, bringing a wide range of consumer graphic design experience to the role of creative artworker.


Sarah Gipps and David Williams 



 

Publicis Life Brands team  

Publicis Life Brands London has appointed Clarissa de Marco and Caroline Blake to the role of account manager, joining senior account manager Susie Jenkyns.The company has also appointed Gemma Cleveland to the position of copywriter and Nick Bartlett to the role of digital strategy director.

Porterhouse Medical Ltd (PML) has restructured and expanded with the formation of a dedicated account development and management team. New appointments include Gavin Coetzee as business development director, Alison Washer as client services director and Teresa Damant and Susie Lee as account managers.


 

Porterhouse Medical Ltd team

 

 

Sarah Philp
 

Sarah Philp has joined Woolley Pau as a senior account director in the client services department. Sarah brings 10 years' industry experience to her new role.

Idis has appointed Richard Greatorex to the position of international marketing manager. He will be based at the company's global headquarters in the UK and will be responsible for developing and managing the portfolio of Idis' products and services for the pharmaceutical and biotechnology industry. Richard joins from CSL Behring where he held the position of regional marketing director — Western Europe (vaccines) from 2006. Richard reports to Andrew Moody, chief marketing officer.


 Richard Greatorex


Pfizer has named Mikael Dolsten, MD, PhD president of worldwide research and development (R&D). Dr Dolsten previously led Wyeth's R&D organisation and, after the close of the Wyeth acquisition, was named president of Pfizer's BioTherapeutics Research & Development. He will now lead all research at Pfizer, as well as development of all compounds through phase II. Late-stage clinical development will continue to be led by clinical teams throughout the Worldwide Biopharmaceutical Businesses.

AstraZeneca has appointed Martin Mackay to the newly created position of president of R&D. Martin, until recently head of PharmaTherapeutics Research & Development at Pfizer, will lead the company's research and development organisation and will have overall accountability for delivering new products from AstraZeneca's pipeline. He will start his new role on July 1 and will be based at AstraZeneca's headquarters in London. Martin will report to David Brennan, chief executive officer, and will be a member of AstraZeneca's senior executive team. 

Patrick Vallance has been appointed senior vice president, medicines discovery and development at GlaxoSmithKline, where he also joins the corporate executive team, both with effect from July 1. Prior to joining GSK in 2006, Patrick was a clinical academic and led the division of medicine at UCL.

Jaimie Brown will join Novartis Oncology as European head of PR and communications in the summer. Jaimie — who joins from Hill & Knowlton, where he was responsible for strengthening the existing senior team in the health and wellbeing practice — will now be based in Novartis Oncology's European headquarters in Milan.

John Marchese has been promoted to the newly created position of executive vice president and director of account services at Sudler & Hennessey (S&H). Marchese joined S&H in 2000 as a traffic co-ordinator.

Euro RSCG Life Medicom has made four new hires to handle new international and domestic business. Antonia Ford and Beth Allgood join as account directors, Sarah Stephenson starts as a senior account executive and Matt Bowskill joins the agency as copywriter.

Ruder Finn has announced the appointment of Judith Cranford as managing director of health, advocacy and alliance development for its London office. Cranford joins from MS&L Worldwide where she was MD of health and advocacy.

Dr Brian Gaffney has been appointed as director of public health at NHS Direct. In the newly created role, Dr Gaffney will be responsible for building on and developing the Trust's relationships with the medical profession including GPs, hospital doctors and those working in public health. Dr Gaffney joined NHS Direct as national public health advisor in October 2009. He will be working part-time for NHS Direct so that he can continue to work in general practice in Northern Ireland.

Jeff Solomon, former leader of not-for-profit bioscience organisation ERBI, has been appointed non-executive advisor to Bioscience NEDs, a company that helps emerging life science businesses find non-executive directors (NEDs) and non-executive chairmen (NECs). Jeff is currently chairman of the Council for European Bioregions and a non-executive director for Myeloma UK and The Cambridge Phenomenon.

Clew Communications has promoted Sheetal Morzaria to account manager. Sheetal's main areas of responsibility will be Novartis vaccines and The Hesley Group, a care provider for people with severe autism.

Digitas Health has made five hires this month. Haifa Barbari joins as senior account manager from VCCP Health where she held a similar position. Paula Stephenson joins as senior medical writer from Great Ormond Street Hospital for Children NHS Trust and the UCL Institute of Child Health. Louise Hart joins as senior account manager from DDB Health and Marcos Richardson, most recently a consultant on search engine optimisation (SEO) and analytics for Omnicom Group (OMD), joins as head of SEO. Finally, Tim Rose joins from EzGov Europe in Amsterdam in the role of senior user experience architect.

Jenny Plant has been promoted to general manager of Publicis Life Brands Resolute, a Publicis Healthcare Communications Group Europe (PHCG) company. In her new role, Jenny will report to Publicis Life Brands Resolute joint managing directors Paul Blackburn and Anna Korving and will be responsible for leading account teams as well as forecasting and driving new business efforts for the agency, with her primary focus being on advertising and branding. Jenny has been with Publicis Life Brands for five years, most recently as client services director.

Ben Fisher has joined OgilvyHealthPR as associate director, where he will head up the Boehringer Ingelheim diabetes portfolio, in addition to focusing on new business. Joining from Porter Novelli, Ben brings ten years' experience in healthcare communications and has worked across a number of disease areas, including respiratory, oncology, women's health, gastroenterology, diabetes and nutrition.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Appointments Commission have appointed two new members to the Committee on the Safety of Devices (CSD). Mr Timothy Wilton, a consultant orthopaedic surgeon at Derbyshire Royal Infirmary, has been appointed as an expert member of orthopaedics and Mr Adrian Harris, lead clinician in the department of emergency medicine for the Royal Devon and Exeter Hospital and chair of the regional board of the College of Emergency Medicine for the South West, has been appointed as an expert member in accident and emergency medicine. 

Dr Ismail Kola, president, new medicines and executive vice president of UCB in Belgium, has joined the board of directors of Astex Therapeutics. Dr Kola holds adjunct professorships of medicine at Washington University, Missouri, US, and at Monash University Medical School, Melbourne, Australia. He is a foreign adjunct professorship at The Karolinska Institute, Stockholm, Sweden, and is a William Pitt Fellow at Pembroke College, Cambridge University, UK.

The European-focused Innovative Medicines Initiative (IMI) has appointed Roch Doliveux, CEO of UCB, to its governing board. The IMI is a public-private partnership between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union. UCB has been a member of the IMI since its inception in 2006, and Roch Doliveux is already an EFPIA board member.

Related links

FAQ: How do I get my move listed

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics